Cytokine release syndrome and immune effector cell‑associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab
Sebastián Ochenduszko(Hospital Universitario Doctor Peset), Lamberto Landete(Hospital Universitario Doctor Peset), C. Françès(Navarre Institute of Health Research), Ana García Feria(Hospital Universitario Doctor Peset), Maria Dolores Torregrosa(Hospital Universitario Doctor Peset), David Martinez(Hospital de La Ribera)
Cited by 5
Related Papers
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|262
Skin Thickness Changes in Normal Aging Skin
|Gerontology|2009|258
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients
|Annals of the Rheumatic Diseases|2007|235
Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients
|Lara D. Veeken|2011|170
Systemic mastocytosis and bone involvement in a cohort of 75 patients
|Annals of the Rheumatic Diseases|2010|163